TY - JOUR
T1 - Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy
AU - Chou, Sunwen
N1 - Funding Information:
I thank Gail Marousek, Victor Wong and Alwin Borgmann for excellent technical assistance, and Kirsten St. George for referring uncharacterized sequence variants for phenotyping. Reagents for recombineering were provided by the Biological Resources Branch of the National Cancer Institute. This work was supported by NIH grant AI39938 and Department of Veterans Affairs research funds.
PY - 2011/4
Y1 - 2011/4
N2 - Background: Cytomegalovirus UL54 DNA polymerase mutations observed in clinical specimens are of diagnostic significance if confirmed to affect antiviral drug susceptibility. Objectives: Validate an updated recombinant phenotyping method to determine the degree of drug resistance conferred by previously uncharacterized UL54 sequence variants, in comparison with known resistance-related mutations. Study design: Bacterial artificial chromosome clones of viral DNA were mutagenized by recombination, transfected to produce live virus and phenotyped by standardized reporter-based yield reduction assays. Results: Sixteen recombinant viruses were constructed, representing baseline sequences, known resistance-related mutations and amino acid changes of unproven significance from clinical specimens. Phenotypes of baseline strains and known mutants were comparable to results from prior methods and helped to resolve some published inconsistencies. Mutations F412L, F412S, L545W were newly confirmed to confer ganciclovir and cidofovir resistance, while Q578H conferred ganciclovir and foscarnet resistance with borderline cidofovir resistance. Some foscarnet-resistant mutants were appreciably growth-retarded. Conclusions: Results add to known exonuclease domain mutations that confer ganciclovir-cidofovir cross-resistance, polymerase domain mutations that confer foscarnet resistance with variably decreased ganciclovir/cidofovir susceptibility, and increase the list of sequence variants with no measurable impact on drug susceptibility. The phenotypic diversity of similar UL54 genotypic variants complicates the interpretation of genotypic resistance testing. Technical improvements are facilitating the phenotyping of remaining unknown sequence variants.
AB - Background: Cytomegalovirus UL54 DNA polymerase mutations observed in clinical specimens are of diagnostic significance if confirmed to affect antiviral drug susceptibility. Objectives: Validate an updated recombinant phenotyping method to determine the degree of drug resistance conferred by previously uncharacterized UL54 sequence variants, in comparison with known resistance-related mutations. Study design: Bacterial artificial chromosome clones of viral DNA were mutagenized by recombination, transfected to produce live virus and phenotyped by standardized reporter-based yield reduction assays. Results: Sixteen recombinant viruses were constructed, representing baseline sequences, known resistance-related mutations and amino acid changes of unproven significance from clinical specimens. Phenotypes of baseline strains and known mutants were comparable to results from prior methods and helped to resolve some published inconsistencies. Mutations F412L, F412S, L545W were newly confirmed to confer ganciclovir and cidofovir resistance, while Q578H conferred ganciclovir and foscarnet resistance with borderline cidofovir resistance. Some foscarnet-resistant mutants were appreciably growth-retarded. Conclusions: Results add to known exonuclease domain mutations that confer ganciclovir-cidofovir cross-resistance, polymerase domain mutations that confer foscarnet resistance with variably decreased ganciclovir/cidofovir susceptibility, and increase the list of sequence variants with no measurable impact on drug susceptibility. The phenotypic diversity of similar UL54 genotypic variants complicates the interpretation of genotypic resistance testing. Technical improvements are facilitating the phenotyping of remaining unknown sequence variants.
KW - Cytomegalovirus
KW - Mutation
KW - Phenotyping
KW - Polymerase
KW - Resistance
UR - http://www.scopus.com/inward/record.url?scp=79952618827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952618827&partnerID=8YFLogxK
U2 - 10.1016/j.jcv.2011.01.004
DO - 10.1016/j.jcv.2011.01.004
M3 - Article
C2 - 21295516
AN - SCOPUS:79952618827
SN - 1386-6532
VL - 50
SP - 287
EP - 291
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
IS - 4
ER -